SWOG clinical trial number
N0724
A Randomized Phase II Study of Oligometastatic Stage IV Non-Small Cell Lung Cancer (NSCLC) Treated with Systemic Therapy plus Either Radiotherapy to all Sites of Gross Residual Disease or No Radiotherapy
Closed
Phase
Abbreviated Title
Rand Ph II Oligometastatic Stage IV NSCLC RT
Activated
06/01/2009
Closed
07/15/2010
Participants
Research committees
Lung Cancer
Treatment
Radiation Therapy
Platinum-based Chemotherapy
Eligibility Criteria Expand/Collapse
Pt must have histo or cyto confirmation of Stage IV NSCLC with previously untreated dz or SD or PR ,/= 8 wks following 1 prev regimen of standard platinum-based chemo given q 3-4 wks for total of 2-6 cycles. Pts w/M1 with 1-3 mets, but no more eligible. Pts must not have hx of or current brain mets, 2nd primary except as noted in Sect 3.22, prior therapies for this cancer other than 2-6 cycles of platinum-based chemo (Note: Bevacizumab is allowed), prior RT to sites which need to be treated.
Other Clinical Trials
SWOG Clinical Trial Number
S2302
PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
95%
Open
Phase
SWOG Clinical Trial Number
A082002
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007
RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open